Company / SG&A Expense
ATOSSA THERAPEUTICS, INC. SG&A Expense History
FY2012-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.8M
FY2016
5-year range
$3.0M / $8.8M
FY2012-FY2016
Trend
+9.9%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 5 years, ranging from $3M in FY2013 to $9M in FY2016.
Based on SEC 10-K filings.
$9M in FY2016 with a 3-year CAGR of +42.7%.
Increased from $9M to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +42.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +42.7%, indicating consistent growth.
- In FY2016, sg&a expense increased 9.9% year-over-year.
- Lowest sg&a expense in the period was in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $8.8M | +9.9% |
| FY2015 | $8.1M | -5.9% |
| FY2014 | $8.6M | +181.1% |
| FY2013 | $3.0M | -4.0% |
| FY2012 | $3.2M | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026